XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaborative Arrangements | 9 Months Ended
--- | ---
Sep. 30, 2022
Collaborative Arrangements [Abstract] |
Collaborative Arrangements | Collaborative Arrangements Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. AstraZeneca In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs. As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400 million. As of September 30, 2022, sales-based milestone payments accrued but not yet paid totaled $600 million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.2 billion remain under the agreement. The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at September 30, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing. Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Alliance revenue - Lynparza | $ | 284 |  |  | $ | 246 |  |  | $ | 825 |  |  | $ | 721 |
Alliance revenue - Koselugo | 10 |  |  | 6 |  |  | 43 |  |  | 20 |
Total alliance revenue | $ | 294 |  |  | $ | 252 |  |  | $ | 868 |  |  | $ | 741 |
Cost of sales (1) | 64 |  |  | 42 |  |  | 425 |  |  | 125 |
Selling, general and administrative | 45 |  |  | 44 |  |  | 135 |  |  | 127 |
Research and development | 28 |  |  | 27 |  |  | 79 |  |  | 87 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Receivables from AstraZeneca included in Other current assets |  |  |  |  | $ | 290 |  |  | $ | 271 |
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2) |  |  |  |  | 12 |  |  | 415 |
Payables to AstraZeneca included in Other Noncurrent Liabilities (2) |  |  |  |  | 600 |  |  | — |
(1) Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above. (2) Includes accrued milestone payments. Eisai In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima. Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement. The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $867 million at September 30, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing. Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Alliance revenue - Lenvima | $ | 202 |  |  | $ | 188 |  |  | $ | 660 |  |  | $ | 498 |
Cost of sales (1) | 53 |  |  | 49 |  |  | 159 |  |  | 143 |
Selling, general and administrative | 42 |  |  | 34 |  |  | 115 |  |  | 88 |
Research and development | 24 |  |  | 43 |  |  | 128 |  |  | 165 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Receivables from Eisai included in Other current assets |  |  |  |  | $ | 202 |  |  | $ | 200 |
Payables to Eisai included in Accrued and other current liabilities (2) |  |  |  |  | 1 |  |  | 625 |
(1) Represents amortization of capitalized milestone payments. (2) Amount as of December 31, 2021 includes accrued milestone payments. Bayer AG In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer. The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $597 million and $53 million, respectively, at September 30, 2022 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Alliance revenue - Adempas/Verquvo | $ | 88 |  |  | $ | 100 |  |  | $ | 258 |  |  | $ | 248 |
Net sales of Adempas recorded by Merck | 57 |  |  | 59 |  |  | 181 |  |  | 188 |
Net sales of Verquvo recorded by Merck | 6 |  |  | 2 |  |  | 15 |  |  | 3 |
Total sales | $ | 151 |  |  | $ | 161 |  |  | $ | 454 |  |  | $ | 439 |
Cost of sales (1) | 55 |  |  | 53 |  |  | 158 |  |  | 328 |
Selling, general and administrative | 42 |  |  | 31 |  |  | 107 |  |  | 84 |
Research and development | 18 |  |  | 16 |  |  | 52 |  |  | 36 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Receivables from Bayer included in Other current assets |  |  |  |  | $ | 144 |  |  | $ | 114 |
Payables to Bayer included in Accrued and other current liabilities (2) |  |  |  |  | 75 |  |  | 472 |
(1) Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. (2) Amount as of December 31, 2021 includes accrued milestone payment. Ridgeback Biotherapeutics LP In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses. Lagevrio has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for Lagevrio in more than 40 markets. As of September 30, 2022, the Company has 0.8 million remaining courses to be supplied under these agreements. Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Lagevrio sales | $ | 436 |  |  | $ | — |  |  | $ | 4,859 |  |  | $ | — |
Cost of sales (1) | 234 |  |  | 4 |  |  | 2,580 |  |  | 56 |
Selling, general and administrative | 41 |  |  | 6 |  |  | 105 |  |  | 13 |
Research and development | 8 |  |  | 58 |  |  | 29 |  |  | 167 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Payables to Ridgeback included in Accrued and other current liabilities (2) |  |  |  |  | $ | 193 |  |  | $ | 283 |
(1) Includes royalty expense and amortization of capitalized milestone payments. (2) Includes accrued royalty and milestone payments. Bristol Myers Squibb Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue of $39 million (consisting of royalties) within Sales in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104 million, as well as the receipt of a regulatory approval milestone payment of $20 million.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -URI https://asc.fasb.org/topic&trid=5833765 + Details
Name: | us-gaap_CollaborativeArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration